Enterococcal infections in patients treated with moxalactam

Area of Science:

• Infectious Diseases
• Pharmacology
• Clinical Microbiology

Background:

• Moxalactam and third-generation cephalosporins exhibit in vitro ineffectiveness against enterococci.
• Enterococcal superinfections represent a potential complication of broad-spectrum antibiotic therapy.

Purpose of the Study:

• To determine the incidence of enterococcal superinfections in patients treated with moxalactam.
• To identify risk factors and clinical outcomes associated with enterococcal superinfections during moxalactam therapy.

Main Methods:

• Retrospective review of 2,107 patient case reports treated with moxalactam.
• Analysis of infection types, presence of enterococci in cultures, and therapeutic outcomes.

Main Results:

• Enterococcal superinfection occurred in 2.1% of patients.
• Superinfections were most common in patients with urinary tract infections and urinary catheter use.
• Seven patients developed enterococcal bacteremia during moxalactam treatment.
• Initial enterococcal presence did not correlate with adverse outcomes in certain infection types (skin, soft tissue, intraabdominal, gynecologic).

Conclusions:

• Moxalactam therapy is associated with a risk of enterococcal superinfection, especially in patients with urinary tract issues.
• Enterococcal bacteremia is a possible complication during moxalactam treatment.
• Further research may be needed to clarify the clinical significance of enterococci in specific infection contexts.